CAS 95734-82-0

Nedaplatin

Description:

Nedaplatin is a platinum-based chemotherapeutic agent, primarily used in the treatment of various cancers, including lung and head and neck cancers. It is a second-generation platinum compound, designed to overcome some of the limitations associated with cisplatin, such as nephrotoxicity and gastrointestinal side effects. Nedaplatin exhibits antitumor activity by forming DNA cross-links, which inhibit DNA replication and transcription, ultimately leading to cancer cell death. Its chemical structure includes a platinum atom coordinated to various ligands, which enhances its solubility and bioavailability compared to its predecessors. Nedaplatin is typically administered intravenously and has been shown to have a different side effect profile, often resulting in less severe nausea and vomiting. However, like other platinum compounds, it can still cause myelosuppression and peripheral neuropathy. Ongoing research continues to explore its efficacy in combination with other therapeutic agents and its potential in treating resistant cancer types. Overall, nedaplatin represents an important option in the arsenal of chemotherapeutic agents for oncologists.

Formula: C₂H₈N₂O₃Pt

InChI: InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1

InChI key: InChIKey=GYAVMUDJCHAASE-UHFFFAOYSA-M

SMILES: [NH3][Pt+2]1([NH3])[O-]C(=O)C[O-]1

Synonyms:

• (Glycolato-O,O')Diammineplatinum(Ii)
• (SP-4-3)-Diammine[2-(hydroxy-κO)acetato(2-)-κO]platinum
• 254-S
• Acetic acid, hydroxy-, platinum complex
• Aqupla
• Cis-Diammine(Glycolato)Platinum(Ii)
• Diammine(Glycolato)Platinum(Ii) Nedaplatin Nsc 375101D
• NSC 375101
• Nedaplait
• O(Sup 2))- Diammine(Hydroxyacetato(2-)-O(Sup 1 (Sp-4-3)-Platinu (Glycolato-O,O')Diammineplatinum(Ii) 254-S Cis-
• O(Sup2))-Diammine(Hydroxyacetato(2-)-O(Sup1(Sp-4-3)-Platinu
• Platinum(2+) Azanide - Hydroxyacetic Acid (1:2:1)
• Platinum, diammine[(hydroxy-κO)acetato(2-)-κO]-, (SP-4-3)-
• Platinum, diammine[2-(hydroxy-κO)acetato(2-)-κO]-, (SP-4-3)-
• Platinum, diammine[hydroxyacetato(2-)-O¹,O²]-, (SP-4-3)-
• S 254
• diamino[(hydroxy-kappaO)acetato(2-)-kappaO]platinum

Platinum, diammine[2-​(hydroxy-​κO)​acetato(2-​)​-​κO]​-​, (SP-​4-​3)​-

CAS: 95734-82-0

Formula: C₂H₆N₂O₃Pt

Purity: 98%

Color and Shape: Solid

Molecular weight: 301.1586

Ref: IN-DA005YCS

Nedaplatin

CAS: 95734-82-0

Nedaplatin, a cisplatin derivative, induces tumor DNA damage (IC50: 94 μM) through platinum-DNA cross-links, causing apoptosis.

Formula: C₂H₈N₂O₃Pt

Purity: 99.88% - >99.99%

Color and Shape: Straw Yellow Powder

Molecular weight: 303.17

Ref: TM-T2410

Nedaplatin

CAS: 95734-82-0

Nedaplatin

Purity: ≥98%

Molecular weight: 303.17g/mol

Ref: 54-BUP11167

Nedaplatin

CAS: 95734-82-0

Formula: C₂H₆N₂O₃Pt

Molecular weight: 301.16

Ref: 7W-GP6527

Nedaplatin

CAS: 95734-82-0

Formula: C₂H₈N₂O₃Pt

Molecular weight: 303.17

Ref: 4Z-N-097001

Nedaplatin

CAS: 95734-82-0

Nedaplatin is a platinum-based anti-cancer drug that has been reported to have significant cytotoxicity against human osteosarcoma cells. It is used in chemotherapy as a radiosensitizer. Nedaplatin can be used to treat cancers that are unresponsive to cisplatin, such as non-small cell lung cancer, ovarian cancer, and breast cancer. Nedaplatin is administered intravenously and has acute toxicities that include nephrotoxicity, neurotoxicity, and ototoxicity. This drug is an anti-cancer compound that has been shown to inhibit the proliferation of cells by binding with DNA at the site of DNA damage and inhibiting DNA repair. The polymer coating on nedaplatin reduces its toxicity by preventing it from entering cells through passive diffusion.

Formula: C₂H₂O₃Pt·2H₃N

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 303.18 g/mol

Ref: 3D-FN65098

(Glycolato-O,O’)diammineplatinum(II)

CAS: 95734-82-0

Formula: C₂H₈N₂O₃Pt

Purity: ≥99%

Molecular weight: 303.181

Ref: 10-F036585